A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait

British Journal of Haematology

Volumn 169, Issue 3, 2015, Pages 435-444

  El Galaly, Tarec Christoffer ^a,b   Bilgrau, Anders E ^a,b   de Nully Brown, Peter ^c   Mylam, Karen J ^d   Ahmad, Syed A ^c   Pedersen, Lars M ^e   Gang, Anne O ^f   Bentzen, Hans H ^g   Juul, Maja B ^h   Bergmann, Olav J ⁱ   Pedersen, Robert S ^j   Nielsen, Berit J ^a,b   Johnsen, Hans E ^a,b   Dybkær, Karen ^a,b   Bøgsted, Martin ^a,b   Hutchings, Martin ^c  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c Rigshospitalet   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e ROSKILDE HOSPITAL   (Denmark)

^f Mental Health Center Glostrup   (Denmark)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h LILLEBAELT HOSPITAL   (Denmark)

ⁱ Esbjerg University Hospital   (Denmark)

^j HOLSTEBRO HOSPITAL   (Denmark)

more..

Author keywords

Follicular lymphoma; Histological transformation; Overall survival; Progression free survival; Watch and wait

Indexed keywords

LACTATE DEHYDROGENASE;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; DISEASE DURATION; DYING; FEMALE; FOLLICULAR LYMPHOMA; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; LYMPHANGIOGENESIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MARGINAL ZONE LYMPHOMA; MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SEX RATIO; VERY ELDERLY; WATCHFUL WAITING; BONE MARROW; CANCER GRADING; HEALTH SURVEY; LYMPHOMA, FOLLICULAR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PATIENT OUTCOME ASSESSMENT; POPULATION SURVEILLANCE; PROGNOSIS; RETROSPECTIVE STUDIES; WATCHFUL WAITING;

EID: 84927693567     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13316     Document Type: Article

References (38)

1. Acker, B., Hoppe, R.T., Colby, T.V., Cox, R.S., Kaplan, H.S. & Rosenberg, S.A. (1983) Histologic conversion in the non-Hodgkin's lymphomas. Journal of Clinical Oncology, 1, 11-16.
2. Al-Tourah, A.J., Gill, K.K., Chhanabhai, M., Hoskins, P.J., Klasa, R.J., Savage, K.J., Sehn, L.H., Shenkier, T.N., Gascoyne, R.D. & Connors, J.M. (2008) Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. Journal of Clinical Oncology, 26, 5165-5169.
3. Ardeshna, K.M., Smith, P., Norton, A., Hancock, B.W., Hoskin, P.J., MacLennan, K.A., Marcus, R.E., Jelliffe, A., Vaughan, G., Hudson, G., Vaughan & Linch, D.C. (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet, 362, 516-522.
4. Ardeshna, K.M., Qian, W., Smith, P., Braganca, N., Lowry, L., Patrick, P., Warden, J., Stevens, L., Pocock, C.F., Miall, F., Cunningham, D., Davies, J., Jack, A., Stephens, R., Walewski, J., Ferhanoglu, B., Bradstock, K. & Linch, D.C. (2014) Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncology, 15, 424-435.
5. Armitage, J.O. & Weisenburger, D.D. (1998) New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. Journal of Clinical Oncology, 16, 2780-2795.
6. Bains, P., Al Tourah, A., Campbell, B.A., Pickles, T., Gascoyne, R.D., Connors, J.M. & Savage, K.J. (2013) Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. Annals of Oncology, 24, 428-432.
7. Brice, P., Bastion, Y., Lepage, E., Brousse, N., Haioun, C., Moreau, P., Straetmans, N., Tilly, H., Tabah, I. & Solal-Celigny, P. (1997) Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 15, 1110-1117.
8. Colombat, P., Brousse, N., Salles, G., Morschhauser, F., Brice, P., Soubeyran, P., Delwail, V., Deconinck, E., Haioun, C., Foussard, C., Sebban, C., Tilly, H., Thieblemont, C., Bergougnoux, L., Lazreg, F. & Solal-Celigny, P. (2012) Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. Annals of Oncology, 23, 2380-2385.
9. Conconi, A., Motta, M., Bertoni, F., Piona, C., Stathis, A., Wannesson, L., Gracia, E., Filho, V.B., Abreu, D.R., Mian, M., Froesch, P., Mazzucchelli, L., Ghielmini, M., Cavalli, F. & Zucca, E. (2010) Patterns of survival of follicular lymphomas at a single institution through three decades. Leukemia and Lymphoma, 51, 1028-1034.
10. Conconi, A., Ponzio, C., Lobetti-Bodoni, C., Motta, M., Rancoita, P.M., Stathis, A., Moccia, A.A., Mazzucchelli, L., Bertoni, F., Ghielmini, M., Cavalli, F. & Zucca, E. (2012) Incidence, risk factors and outcome of histological transformation in follicular lymphoma. British Journal of Haematology, 157, 188-196.
11. Cullen, M.H., Lister, T.A., Brearley, R.I., Shand, W.S. & Stansfeld, A.G. (1979) Histological transformation of non-Hodgkin's lymphoma: a prospective study. Cancer, 44, 645-651.
12. Dreyling, M., Ghielmini, M., Marcus, R., Salles, G. & Vitolo, U. (2011) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 22 (Suppl 6), vi59-vi63.
13. Friedberg, J.W., Taylor, M.D., Cerhan, J.R., Flowers, C.R., Dillon, H., Farber, C.M., Rogers, E.S., Hainsworth, J.D., Wong, E.K., Vose, J.M., Zelenetz, A.D. & Link, B.K. (2009) Follicular lymphoma in the United States: first report of the national LymphoCare study. Journal of Clinical Oncology, 27, 1202-1208.
14. Gang, A.O., Strøm, C., Pedersen, M., d'Amore, F., Pedersen, L.M., Bukh, A., Pedersen, B.B., Moeller, M.B., Mortensen, L.S., Gadeberg, O.V., Ingeberg, S., Mourits-Andersen, T., Pulczynski, S. & d Nully Brown, P. (2012) R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. Annals of Oncology, 23, 147-153.
15. Ghielmini, M., Schmitz, S.F., Cogliatti, S.B., Pichert, G., Hummerjohann, J., Waltzer, U., Fey, M.F., Betticher, D.C., Martinelli, G., Peccatori, F., Hess, U., Zucca, E., Stupp, R., Kovacsovics, T., Helg, C., Lohri, A., Bargetzi, M., Vorobiof, D. & Cerny, T. (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood, 103, 4416-4423.
16. Gray, B. (2014) cmprsk: Subdistribution Analysis of Competing Risks. R package version 2.2-7. URL http://CRAN.R-project.org/package=cmprsk. [Accessed December 3, 2014].
17. Guirguis, H.R., Cheung, M.C., Piliotis, E., Spaner, D., Berinstein, N.L., Imrie, K., Zhang, L. & Buckstein, R. (2014) Survival of patients with transformed lymphoma in the rituximab era. Annals of Hematology, 93, 1007-1014.
18. Herold, M., Haas, A., Srock, S., Neser, S., Al-Ali, K.H., Neubauer, A., Dolken, G., Naumann, R., Knauf, W., Freund, M., Rohrberg, R., Hoffken, K., Franke, A., Ittel, T., Kettner, E., Haak, U., Mey, U., Klinkenstein, C., Assmann, M. & von Grunhagen, U. (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. Journal of Clinical Oncology, 25, 1986-1992.
19. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H.E., Freund, M., Wormann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trumper, L., Aldaoud, A., Parwaresch, R. & Unterhalt, M. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, 3725-3732.
20. Horning, S.J. & Rosenberg, S.A. (1984) The natural history of initially untreated low-grade non-Hodgkin's lymphomas. New England Journal of Medicine, 311, 1471-1475.
21. Hubbard, S.M., Chabner, B.A., DeVita, V.T. Jr, Simon, R., Berard, C.W., Jones, R.B., Garvin, A.J., Canellos, G.P., Osborne, C.K. & Young, R.C. (1982) Histologic progression in non-Hodgkin's lymphoma. Blood, 59, 258-264.
22. Johnson, P.W., Rohatiner, A.Z., Whelan, J.S., Price, C.G., Love, S., Lim, J., Matthews, J., Norton, A.J., Amess, J.A. & Lister, T.A. (1995) Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. Journal of Clinical Oncology, 13, 140-147.
23. Kahl, B.S., Hong, F., Williams, M.E., Gascoyne, R.D., Wagner, L.I., Krauss, J.C., Habermann, T.M., Swinnen, L.J., Schuster, S.J., Peterson, C.G., Sborov, M.D., Martin, S.E., Weiss, M., Ehmann, W.C. & Horning, S.J. (2014) Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol E4402. Journal of Clinical Oncology, 32, 3096-3102.
24. Link, B.K., Maurer, M.J., Nowakowski, G.S., Ansell, S.M., Macon, W.R., Syrbu, S.I., Slager, S.L., Thompson, C.A., Inwards, D.J., Johnston, P.B., Colgan, J.P., Witzig, T.E., Habermann, T.M. & Cerhan, J.R. (2013) Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. Journal of Clinical Oncology, 31, 3272-3278.
25. Liu, Q., Fayad, L., Cabanillas, F., Hagemeister, F.B., Ayers, G.D., Hess, M., Romaguera, J., Rodriguez, M.A., Tsimberidou, A.M., Verstovsek, S., Younes, A., Pro, B., Lee, M.S., Ayala, A. & McLaughlin, P. (2006) Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. Journal of Clinical Oncology, 24, 1582-1589.
26. Marcus, R., Imrie, K., Solal-Celigny, P., Catalano, J.V., Dmoszynska, A., Raposo, J.C., Offner, F.C., Gomez-Codina, J., Belch, A., Cunningham, D., Wassner-Fritsch, E. & Stein, G. (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. Journal of Clinical Oncology, 26, 4579-4586.
27. Martinelli, G., Schmitz, S.F., Utiger, U., Cerny, T., Hess, U., Bassi, S., Okkinga, E., Stupp, R., Stahel, R., Heizmann, M., Vorobiof, D., Lohri, A., Dietrich, P.Y., Zucca, E. & Ghielmini, M. (2010) Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. Journal of Clinical Oncology, 28, 4480-4484.
28. Okosun, J., Bodor, C., Wang, J., Araf, S., Yang, C.Y., Pan, C., Boller, S., Cittaro, D., Bozek, M., Iqbal, S., Matthews, J., Wrench, D., Marzec, J., Tawana, K., Popov, N., O'Riain, C., O'Shea, D., Carlotti, E., Davies, A., Lawrie, C.H., Matolcsy, A., Calaminici, M., Norton, A., Byers, R.J., Mein, C., Stupka, E., Lister, T.A., Lenz, G., Montoto, S., Gribben, J.G., Fan, Y., Grosschedl, R., Chelala, C. & Fitzgibbon, J. (2014) Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nature Genetics, 46, 176-181.
29. Pasqualucci, L., Khiabanian, H., Fangazio, M., Vasishtha, M., Messina, M., Holmes, A.B., Ouillette, P., Trifonov, V., Rossi, D., Tabbo, F., Ponzoni, M., Chadburn, A., Murty, V.V., Bhagat, G., Gaidano, G., Inghirami, G., Malek, S.N., Rabadan, R. & Dalla-Favera, R. (2014) Genetics of follicular lymphoma transformation. Cell Reports, 6, 130-140.
30. Portlock, C.S. & Rosenberg, S.A. (1979) No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. Annals of Internal Medicine, 90, 10-13.
31. R Core Team. (2013) R: A language and environment for statistical computing. R Foundation for Statistical Computing. URL http://www.R-project.org/. [Accessed December 3, 2014].
32. Solal-Celigny, P., Lepage, E., Brousse, N., Tendler, C.L., Brice, P., Haioun, C., Gabarre, J., Pignon, B., Tertian, G., Bouabdallah, R., Rossi, J.F., Doyen, C. & Coiffier, B. (1998) Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. Journal of Clinical Oncology, 16, 2332-2338.
33. Solal-Celigny, P., Roy, P., Colombat, P., White, J., Armitage, J.O., Arranz-Saez, R., Au, W.Y., Bellei, M., Brice, P., Caballero, D., Coiffier, B., Conde-Garcia, E., Doyen, C., Federico, M., Fisher, R.I., Garcia-Conde, J.F., Guglielmi, C., Hagenbeek, A., Haioun, C., LeBlanc, M., Lister, A.T., Lopez-Guillermo, A., McLaughlin, P., Milpied, N., Morel, P., Mounier, N., Proctor, S.J., Rohatiner, A., Smith, P., Soubeyran, P., Tilly, H., Vitolo, U., Zinzani, P.L., Zucca, E. & Montserrat, E. (2004) Follicular lymphoma international prognostic index. Blood, 104, 1258-1265.
34. Solal-Celigny, P., Bellei, M., Marcheselli, L., Pesce, E.A., Pileri, S., McLaughlin, P., Luminari, S., Pro, B., Montoto, S., Ferreri, A.J., Deconinck, E., Milpied, N., Gordon, L.I. & Federico, M. (2012) Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. Journal of Clinical Oncology, 30, 3848-3853.
35. STATBANK, downloaded from the statbank (http://www.statbank.dk/statbank5a/default.asp?w=1280) [Accessed June 1, 2014].
36. Tan, D., Horning, S.J., Hoppe, R.T., Levy, R., Rosenberg, S.A., Sigal, B.M., Warnke, R.A., Natkunam, Y., Han, S.S., Yuen, A., Plevritis, S.K. & Advani, R.H. (2013) Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood, 122, 981-987.
37. Therneau, T. (2014) A Package for Survival Analysis in S. R package version 2.37-7. URL http://CRAN.R-project.org/package=survival. [Accessed December 3, 2014].
38. Young, R.C., Longo, D.L., Glatstein, E., Ihde, D.C., Jaffe, E.S. & DeVita, V.T. Jr (1988) The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Seminars in Hematology, 25, 11-16.